Le Lézard
Classified in: Covid-19 virus
Subjects: NPT, TDS, ASI, DEI

President Biden's Deputy Assistant to Speak on Anti-Asian Hate Crimes for G20 Interfaith Forum's Anti-Racism Initiative


WASHINGTON, June 10, 2021 /PRNewswire/ -- President Joe Biden's newly appointed Deputy Assistant, Erika Moritsugu, will address anti-Asian hate and discrimination in an upcoming public webinar hosted by the G20 Interfaith Forum Association (IF20). Moritsugu, along with five other distinguished leaders, will present at 11:00 am EDT on June 10, 2021. This webinar is one of the many actions IF20 is taking as part of its Anti-Racism Initiative.

"Across our nation, an outpouring of grief and outrage continues at the horrific violence... against Asian American[s}."

 Moritsugu was appointed by President Joseph R. Biden in April 2021 to serve as Deputy Assistant to the President and Asian American (AA) and Native Hawaiian and Pacific Islander (NHPI) Senior Liaison. She supports leaders through a whole-of-government approach to racial justice.

"Across our nation, an outpouring of grief and outrage continues at the horrific violence and xenophobia perpetrated against Asian American communities, especially Asian American women and girls," Moritsugu said. "As President Biden said during his first prime time address, anti-Asian violence and xenophobia is wrong, it's un-American, and it must stop."

Other featured speakers include:

The webinar will provide a platform for mutual discussion and learning?recognizing what Asian-Americans have experienced during the COVID-19 pandemic.

"For more than a year, Asian Americans have been fighting two viruses: the COVID-19 pandemic and anti-Asian hate," said U.S. Congresswoman Grace Meng. "The COVID-19 Hate Crimes Act that I introduced with Senator Mazie Hirono was signed into law last month by President Biden, and it will go a long way towards combatting this rise in xenophobia and racist attacks."

"In order to recover from and repair the harm to our communities, we need to share our experiences with each other and with those outside of our community," Assemblymember David Chiu said. "Confronting these awful incidents head-on strengthens us and chips away at the ignorance, fear and racism that has spurred these acts of hate."

"What I want to make sure everyone understands, when things happen to you, be calm and understand how to protect yourself as much as you can," Carl Chan of the OCCC stated. "I had to stand strong. I cannot be allowing myself to be a victim, or other people to become victims of crime. So that is the reason why I have to speak out." 

"A strong, successful society is built on ensuring people feel welcome and recognized for their contributions," added Jacinta Ma of the EEOC. "Violence, harassment, and discrimination because someone is or is perceived to be of Asian descent must not be tolerated. Governments, leaders, and individuals all have a role to play in addressing anti-Asian violence."

 

SOURCE G20 Interfaith Forum Association


These press releases may also interest you

at 02:28
Allied Market Research published a report, titled, "Pet Insurance Market by Policy Coverage (Accident Only, Accident and Illness, and Others), Animal Type (Dogs, Cats, and Others), and Sales Channel (Agency, Broker, and Others): Global...

at 02:00
Bradda Head Lithium Ltd (AIM:BHL), the North America-focused lithium development group, is pleased to announce that it has come to a settlement regarding the fraudulent payment first notified on 29 March 2022 and subsequently disclosed in the audited...

at 00:25
Zai Lab Limited and Innoviva Specialty Therapeutics today announced that China's National Medical Products Administration (NMPA) has approved Zai Lab's New Drug Application (NDA) for XACDURO® (sulbactam-durlobactam) for the treatment of...

19 mai 2024
ICIS, a global source of commodity intelligence, has announced the 16th Asian Base Oils and Lubricants Conference will take place in Singapore, 27-28 June 2024. The event offers a platform for senior executives to connect with peers, potential...

19 mai 2024
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

19 mai 2024
Amgen and AstraZeneca today announced the results of the Phase 2a COURSE trial evaluating Tezspire® (tezepelumab-ekko) in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of baseline blood...



News published on and distributed by: